Emergex Vaccines has secured $11 million funding.
Abingdon biotechnology company firm develops set-point vaccines to prevent some of the world’s most immediate and virulent diseases such as Zika, Dengue Fever, Ebola and pandemic flu.
The Series A round was led by Vickers Venture Partners. Dr Finian Tan, chairman of Vickers Venture Partners, has joined Emergex’s board of directors.
Professor Thomas Rademacher, CEO and co-founder of Emergex, commented: “Attracting such high calibre investors is an endorsement of our development pipeline and validation of the potential our technologies hold in the field of infectious diseases.
“These new funds will support us to achieve some significant value-enhancing milestones as we progress our lead vaccine candidates into clinical development.”
Emergex’s underlying platform technology enables rapid development of vaccines to entire families of pathogens, compared to traditional approaches that can take years to develop and scale vaccines for single pathogens.
As purely synthetic vaccines with no biological components, Emergex’s vaccines are much safer as they carry no infection risk from live attenuated pathogens; are much cheaper to produce since they do not require culturing; and can be conveniently transported and administered even in remote parts of the world as they can be stored and handled at room temperature.